CLINICAL RESPONSE TO ANTICOAGULANTS (ACENOCOUMAROL, WARFARIN): CLINICAL EXOME PANEL (Sec. & CNVs) – 3 genes
Delivery time
3-4 weeks
Sample
Blood
The Clinical Response to Anticoagulants panel is designed to analyze genetic variants that influence sensitivity, metabolism, and therapeutic response to oral coumarin anticoagulants such as acenocoumarol and warfarin. These genetic differences can significantly affect the required dose, INR stabilization time, and the risk of bleeding or thrombosis. The study includes the VKORC1 gene, which encodes the target enzyme of vitamin K antagonists and determines drug sensitivity; CYP2C9, responsible for their hepatic metabolism, whose variants reduce drug clearance and increase toxicity; and CYP4F2, involved in vitamin K metabolism and the regulation of the optimal dose. Genetic analysis allows for personalized treatment adjustments, improving safety, efficacy, and anticoagulant control. Key genes analyzed: VKORC1, CYP2C9, and CYP4F2.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€